About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00108758

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment ...

Lead sponsor: Novo Nordisk A/S•13 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Novo Nordisk A/S

Age

2 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of congenital haemophilia A or B with inhibitors development against FVIII or FIX, respectively

Exclusion Criteria

•Prophylactic administration of any haemostatic drug within 3 last months prior to entering the trial.

Related studies

COMPLETEDPhase 3

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

NCT02137850 · Congenital Bleeding Disorder, Haemophilia A

COMPLETEDPhase 3

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

NCT02141074 · Congenital Bleeding Disorder, Haemophilia B

COMPLETEDPhase 3

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

NCT05878938 · Haemophilia A, Haemophilia A With Inhibitors

COMPLETEDPhase 1

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

NCT03075670 · Congenital Bleeding Disorder, Haemophilia B

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

NCT03179748 · Congenital Bleeding Disorder, Haemophilia A

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 12, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment23

Start dateMar 2004

Last updatedJan 12, 2017

Condition

Congenital Bleeding Disorder Haemophilia A With Inhibitors Haemophilia B With Inhibitors

Locations shown

Novo Nordisk Investigational Site

Berkeley, California

Novo Nordisk Investigational Site

Los Angeles, California

Novo Nordisk Investigational Site

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2017Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions